GSK, Genmab Submit sBLA for Arzerra in CLL

Covers combination alkylator-based therapy for CLL

GlaxoSmithKline and Genmab have submitted a sBLA to the FDA for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, for the treatment of Chronic Lymphocytic Leukemia (CLL) in patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
 
The application is based on results from an international, multi-center, randomized Phase III study of Arzerra in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters